Literature DB >> 12180229

Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis.

Mika-P Raitanen1, Risto Aine, Erkki Rintala, Jukka Kallio, Pertti Rajala, Harri Juusela, Teuvo L J Tammela.   

Abstract

OBJECTIVES: The objective of the study is to evaluate the agreement of local and review urinary cytology in patients with newly diagnosed bladder cancer and in those being followed for their disease. In addition, the effect of the type of institution on agreement was determined.
METHODS: A total of 652 consecutive patients with bladder cancer from 19 institutions were evaluated; 575 (88.2%) of the patients had cytopathological sample available for central review and were eligible for analysis. One hundred and twenty nine (22.4%) of the patients had newly diagnosed bladder cancer, whereas the remaining 446 (77.6%) patients were under follow-up. A voided urine sample was obtained prior to transurethral resection of the bladder (TURB) or routine follow-up cystoscopy and split for culture and cytology. The cytopathological samples were first analysed by a local pathologist, and then re-analysed by a central reviewer. The agreement of cytological readings was determined by Kappa coefficient.
RESULTS: The sensitivities of local and review cytology in detection of primary bladder cancer were 38.8 and 31.0%, respectively. Recurrence was observed in 119 of the 446 (26.7%) patients under follow-up, of which both local and review cytology detected 21 (17.6%) cases. Specificities of local and review cytology were 97.6 and 96.6%, respectively. Overall agreement of urine cytology was good in patients with primary bladder cancer and moderate in those being followed for their disease as Kappa coefficients were 0.70 and 0.60, respectively. However, some disagreement was found when results were analysed according to type of institution, to type of primary tumour, and to result of follow-up cystoscopy. In patients with primary bladder cancer the Kappa coefficient was 0.86 (very good) in university hospitals and 0.36 (fair) in city hospitals. Accordingly, in patients under follow-up the Kappa coefficient was 0.65 (good) in university hospitals and 0.39 (fair) in district hospitals. Although the stage of primary tumour had no effect on agreement, agreement was moderate (Kappa coefficient 0.45) in those with low grade tumour and good (Kappa coefficient 0.67) in those with high grade tumour. In addition, Kappa coefficients were 0.65 (good) and 0.40 (fair) in those with and without recurrence at follow-up cystoscopy.
CONCLUSIONS: Although overall agreement of routine cytology was from moderate to good in both diagnosis and monitoring of bladder cancer, there is some variation in agreement according to the type of institution. Accordingly, grade of primary tumour and the result of follow-up cystoscopy had effect on agreement reflecting subjectiveness and weak reproducibility of this test. This not only emphasises the need for continuing education and quality control for urine cytologic analysis, but also inspires the development of more objective tests.

Entities:  

Mesh:

Year:  2002        PMID: 12180229     DOI: 10.1016/s0302-2838(02)00006-4

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  60 in total

1.  Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: Detection of bladder cancer.

Authors:  I Sokolov; M E Dokukin; V Kalaparthi; M Miljkovic; A Wang; J D Seigne; P Grivas; E Demidenko
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

2.  The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Authors:  Mika-P Raitanen
Journal:  World J Urol       Date:  2008-01-08       Impact factor: 4.226

Review 3.  Is there a rationale for bladder cancer screening?

Authors:  Robert S Svatek; Yair Lotan
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

Review 4.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

5.  Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.

Authors:  Hyebin Lee; Kwangsoo Kim; Jongmin Woo; Joonho Park; Hyeyoon Kim; Kyung Eun Lee; Hyeyeon Kim; Youngsoo Kim; Kyung Chul Moon; Ji Young Kim; In Ae Park; Bo Bae Shim; Ji Hye Moon; Dohyun Han; Han Suk Ryu
Journal:  Mol Cell Proteomics       Date:  2018-06-27       Impact factor: 5.911

6.  [Aftercare of non-muscle invasive bladder cancer].

Authors:  G B Schulz; B Schlenker; C G Stief
Journal:  Urologe A       Date:  2019-08       Impact factor: 0.639

7.  Influence of age on false positive rates of urine-based tumor markers.

Authors:  M Horstmann; T Todenhöfer; J Hennenlotter; S Aufderklamm; J Mischinger; U Kuehs; G Gakis; A Stenzl; C Schwentner
Journal:  World J Urol       Date:  2012-07-18       Impact factor: 4.226

8.  Screening for bladder cancer: the best opportunity to reduce mortality.

Authors:  Yves Fradet
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 9.  Diagnosis and management of intradiverticular bladder tumours.

Authors:  Nicholas Faure Walker; Christine Gan; Jonathon Olsburgh; Muhammad Shamim Khan
Journal:  Nat Rev Urol       Date:  2014-06-17       Impact factor: 14.432

10.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.